Ibrutinib induces responses in aggressive lymphomas: Dr Louis Staudt - National Cancer Institute, Bethesda, Maryland, USA

Update: 2012-05-23

Description

Preliminary results from clinical trials in a subtype of lymphoma show that for a number of patients whose disease was not cured by other treatments, the drug ibrutinib can provide significant anti-cancer responses with modest side effects.

Early results from the trial were presented at AACR 2012 in Chicago.

Comments

In Channel

Effects of vitamin D on prostate cancer: Prof Reinhold Vieth - University of Toronto, Ontario, Canada

2012-05-2406:42

Cancer in the developing world: Dr Tim Rebbeck - University of Pennsylvania, Philadelphia, USA

2012-05-2406:20

Metformin's effect on breast cancer: Dr Vuk Stambolic - Ontario Cancer Institute, Toronto, Canada

2012-05-2403:45

Noninvasive imaging markers in prostate cancer: Dr Michael Evans - Memorial Sloan-Kettering Cancer Center, New York, USA

2012-05-2404:08

EGFR mutation unique to glioblastoma linked to lack of response: Dr Ingo Mellinghoff - Memorial Sloan-Kettering Cancer Center

2012-05-2408:04

Biomarker identified in relation to pazopanib in urothelial cancer: Dr Andrea Necchi - National Cancer Institute of Milan

2012-05-2408:08

Anti-angiogenic agents and cancer stem cells: Dr Max Wicha - University of Michigan, Ann Arbor, USA

2012-05-2408:14

Non invasive biomarkers for prostate cancer

2012-05-2405:35

Hypoxia influenced tumour behaviour in prostate cancer: Dr Michael Milosevic - University of Toronto, Ontario, Canada

2012-05-2406:23

Ibrutinib induces responses in aggressive lymphomas: Dr Louis Staudt - National Cancer Institute, Bethesda, Maryland, USA

2012-05-2308:19

Selumetinib controlled recurrent low-grade serous ovarian cancer: Dr John Farley - Creighton University, Phoenix, Arizona, USA

2012-05-2306:30

Galeterone safe and effective against prostate cancer: Dr Bruce Montgomery - University of Washington, Seattle, USA

2012-05-2305:25

$Targeted therapy for refractory Ewing’s Sarcoma tumours: Dr Aung Naing -University of Texas MD Anderson Cancer Center$

Targeted therapy for refractory Ewing’s Sarcoma tumours: Dr Aung Naing -University of Texas MD Anderson Cancer Center

2012-05-2304:06

Metformin to slow prostate cancer growth: Dr Anthony Joshua - Princess Margaret Hospital, Toronto, Canada

2012-05-2305:15

Targeting the cancer genome: Dr Bill Sellers - Novartis Institutes for Biomedical Research, Cambridge, Massachusetts

2012-05-2309:32

Effects of metformin in pancreatic cancer with diabetes: Prof Donghui Li - University of Texas MD Anderson Cancer Center

2012-05-2303:06

Nutrition and supplements for cancer survivors: Prof Susan Mayne - Yale University, Connecticut, USA

2012-05-0910:08

00:00

Ibrutinib induces responses in aggressive lymphomas: Dr Louis Staudt - National Cancer Institute, Bethesda, Maryland, USA

#box-pro-ellipsis-176241566806169{-webkit-line-clamp:2;}Ibrutinib induces responses in aggressive lymphomas: Dr Louis Staudt - National Cancer Institute, Bethesda, Maryland, USA

Ibrutinib induces responses in aggressive lymphomas: Dr Louis Staudt - National Cancer Institute, Bethesda, Maryland, USA

ecancer.org

Ibrutinib induces responses in aggressive lymphomas: Dr Louis Staudt - National Cancer Institute, Bethesda, Maryland, USA